Pharmaceutical News and Articles

Tdap, MenACWY Coverage Increased in Teens From 2023 to 2024

From 2023 to 2024, coverage with one or more doses of the tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine (Tdap) and the quadrivalent

Measles Outbreak in Texas Is Over After Hundreds Infected and 2 Deaths

TUESDAY, Aug. 19, 2025 The measles outbreak in Texas that sickened more than 700 people earlier this year is officially over, state health officials said Monday

Nasal Spray Flu Vaccine, FluMist, Now Available for At-Home Use

TUESDAY, Aug. 19, 2025 For the first time, people can get their annual flu vaccine without leaving the comfort of home. FluMist, a nasal spray flu vaccine made

More People Turning to Over-the-Counter Birth Control Pill, Opill, Study Says

TUESDAY, Aug. 19, 2025 Two years after U.S. approval of the first over-the-counter (OTC) birth control pill, new research shows many people who face barriers to

Two Doses of Zoster Vaccine Reduce Risk for Herpes Zoster Ophthalmicus

Two doses of recombinant zoster vaccine (RZV) are associated with a reduced risk for herpes zoster ophthalmicus (HZO), acute myocardial infarction, and stroke a

AAP Offers Guidance for Tapering of Opioids to Prevent Withdrawal in Children

A plan for tapering opioids should be developed to minimize withdrawal symptoms in children receiving opioids for five or more days, according to a clinical rep

GERD Linked to Increased Incidence of Pulmonary Disease

The presence of gastroesophageal reflux disease (GERD) is associated with an increased incidence of pulmonary diseases, but this effect may be attenuated with G

Intensive Systolic BP Target Cost-Effective for Patients at High Cardiovascular Risk

For patients 50 years or older at high cardiovascular risk without diabetes or prior stroke, an intensive systolic blood pressure (SBP) target ( 120 mm Hg) seem

Diabetes Risk Commonly Clustered Within Households

Diabetes risk is commonly clustered within households, according to a study scheduled to be presented at the annual meeting of the European Association for the

PTC Therapeutics Receives Complete Response Letter for Vatiquinone NDA